Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Christopher J. Hoimes, Matthew D. Galsky, Begoña P. Valderrama, Marco Maruzzo, Albert Font, Tudor-Eliade Ciuleanu, Jonathan Alexander Chatzkel, Takuya Koie, Javier Puente, Yousef Zakharia, Eli Rosenbaum, Katharina Boehm, Yohann Loriot, Jens Bedke, Heidi Wirtz, Mike Mihm, Qinlei Huang, Aljosja Rogiers, Blanca Homet Moreno, Alfonso Gomez De Liaño Lista
Institutions: Duke Medical Center, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Hospital Universitario Virgen del Rocío, Istituto Oncologico Veneto, Institut Català d'Oncologia, Iuliu Hațieganu University of Medicine and Pharmacy, Institute of Oncology Prof. Dr. Ion Chiricuta, Moffitt Cancer Center, University of Florida, UF Health Cancer Center, Gifu University Hospital, Hospital Clínico San Carlos, Mayo Clinic in Arizona, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona), Rabin Medical Center, University Hospital Carl Gustav Carus, Université Paris-Saclay, Institut Gustave Roussy, Klinikum Stuttgart, Pfizer (United States), Astellas Pharma (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Universidad de Las Palmas de Gran Canaria, Hospital Universitario Insular de Gran Canaria
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162501996
Cites:
Cited by:
Related to: